Bristol-Myers Squibb Company company logo

# 1st Gen Model Bristol-Myers Squibb Company Pharmaceutical preparations

Subscribe >> Deal exit on
Dec. 18, 2017
Deal entry on
Dec. 18, 2017
0.61%Expected margin
67.65% successful of 34 deals
$62.41 Last close price
at 15-dec-2017


Model's trade recommendations 1.36% Return for period

-3.63% Annual return

$103.88B Market Cap

β 1.18  


Model (following trade recommendations)


Underlying stock

S&P 500

Return for period 1.36%
52wk return 1.33%
52wk Range
Sortino ratio -0.59
Sharpe ratio -0.54
Norm. RMSE 0.21%
Downside risk 6.35%
Volatility 7.04%
  • 1.56 (2.46%) Div (Yield)
  • BUY Analysts consensus recommendation

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection (HIV). Its products include Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Opdivo, a human monoclonal antibody to treat renal cell carcinoma, non-small cell lung cancer, classical Hodgkin lymphoma, gastric cancer, melanoma, metastatic urothelial carcinoma, and squamous cell carcinoma of the head and neck; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; and Yervoy, a monoclonal antibody for metastatic melanoma.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Bristol-Myers Squibb Company (BMY) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 2, 2015.

Market data for BMY model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 1633M
P/E 21.44
Shares Outstanding 1637M
% Held by Insiders 0.23%
% Held by Institutions 69.82%
EPS (last reported FY) $2.83
EPS (last reported Q) $0.75
EPS, estimated (last reported Q) $0.77
Total revenues $19 B
Net income $4 B